A Rising Hope of an Artificial Heart: Left Ventricular Assisted Device - Outcome, Convenience, and Quality of Life

Oral health-related quality of life in patients with heart failure and left ventricular assist devices-results of a cross-sectional study

Objectives

The aim of this cross-sectional study was to compare oral health-related quality of life (OHRQoL) of patients with left ventricular assist device (LVAD) and heart failure (HF).

Material and methods

Seventy-four patients with LVAD were recruited from University Department for Cardiac Surgery, Leipzig Heart Center, Germany. A group of 72 patients with HF was composed by matching (age, gender, smoking). The German short form of oral health impact profile (OHIP G14) was applied. Health-related quality of life (HRQoL) was measured by short form 36 survey (SF-36). Dental conditions (decayed-, missing- and filled-teeth [DMF-T]), remaining teeth and periodontal findings were assessed. Statistics: t-test, Mann-Whitney U test, Kruskal-Wallis test, chi-square or Fisher test, linear regression.

Results

Age, gender, smoking, underlying disease, co-morbidities and oral findings were comparable between groups (p > 0.05). OHIP G14 sum score was 3.53 ± 6.82 (LVAD) and 2.92 ± 5.35 (HF; p = 0.70), respectively. The scales SF-36 physical functioning (p = 0.05) and SF-36 social functioning (p < 0.01) were worse in LVAD. In the LVAD group, the DMF-T and remaining teeth negatively correlated with OHIP G14 sum score (p < 0.01). In HF patients, positive correlations were found between OHIP G14 and D-T (p < 0.01) and remaining teeth (p = 0.04). Moreover, DMF-T (p = 0.03) and remaining molars/premolars (p = 0.02) were negatively correlated with SF-36 scales in HF.

Conclusions

Oral health and OHRQoL was comparable between LVAD and HF; thereby, OHRQoL reflected the clinical oral status.

Clinical relevance

Dental care, with beginning in early stage of HF, should be fostered to preserve teeth and support quality of life before and after LVAD implantation.

Ventricular Assist Devices and Their Usage as a Bridge to Recovery in Patients With Acute Cardiotoxicity and Cardiomyopathy

Cardiotoxicity can reduce the heart's function temporarily and is most commonly caused by radiation, immune reactions, and certain medications. Using a left ventricular assist device (LVAD) as a bridging therapy while waiting for cardiac recovery has been popular lately in patients who have a reduced ejection fraction after significant cardiac injury. Here we analyze the use of LVAD as a bridging therapy in three cases with chemotherapy-induced cardiotoxicity, acute myocarditis, and postpartum cardiac failure. Although LVADs are infamous for their device-related complications, the ejection fraction can increase up to 50% within days to months of usage without any complications in acute cardiotoxic patients that have no underlying significant risk factors or co-morbidities. Hence LVADs are excellent supportive devices while waiting for cardiac recovery, both in maintaining cardiac function and improving the associated organ failures.